Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice
Articolo
Data di Pubblicazione:
2021
Abstract:
The development of treatment-related adverse events (trAE) correlates favorably with clinical outcomes in multiple studies of patients receiving immune checkpoint inhibitors (ICI); however, this relationship is undefined in patients with hepatocellular carcinoma (HCC).
Tipologia CRIS:
1.1 Articolo in rivista
Keywords:
HCC; Immune-related adverse events; Immunotherapy; Response; Survival; Toxicity
Elenco autori:
Pinato, David J; Marron, Thomas U; Mishra-Kalyani, Pallavi Shruti; Gong, Yutao; Wei, Guo; Szafron, David; Sharon, Elad; Saeed, Anwaar; Jun, Tomi; Dharmapuri, Sirish; Naqash, Abdul R; Peeraphatdit, Thoetchai; Gampa, Anuhya; Wang, Yinghong; Khan, Uqba; Muzaffar, Mahvish; Navaid, Musharraf; Lee, Chieh J; Lee, Pei-Chang; Bulumulle, Anushi; Yu, Bo; Paul, Sonal; Nimkar, Neil; Bettinger, Dominik; Hildebrand, Hannah; Abugabal, Yehia I; Pressiani, Tiziana; Personeni, Nicola; D'Alessio, Antonio; Kaseb, Ahmed O; Huang, Yi-Hsiang; Ang, Celina; Schneider, Julie; Pillai, Anjana; Rimassa, Lorenza; Goldberg, Kirsten B; Pazdur, Richard; Theoret, Marc; Lemery, Steven; Fashoyin-Aje, 'Lola; Cortellini, Alessio; Pelosof, Lorraine
Link alla scheda completa:
Pubblicato in: